AstraZeneca's Alexion, Arvinas nab space at future 10-story biotech tower in New Haven

Some biotechs are building as others crumble, with several industry players—including Alexion Pharmaceuticals and Arvinas—involved in plans for a new 10-floor tower built for burgeoning biotechs.

Last July, AstraZeneca announced a $39 billion acquisition of Alexion, immediately giving the U.K. pharma's top line a $6 billion bump thanks to Alexion’s blockbuster C5 inhibitor franchises, Soliris and Ultomiris. At the time of the deal, the pharma giant said it anticipated Alexion’s drugs to grow 9% per year through 2023.